You are here:
LinkedIn-button

About us

About
Intravacc

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.

The Netherlands-based Intravacc, part of the Utrecht Science Park location Bilthoven, is one of the world’s leading organizations with many years of experience in translational vaccinology. As an established independent clinical development and manufacturing organization (CDMO) in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.

LEARN MOREANNUAL REPORT 2020
LinkedIn-button

Our Vision

To reduce human diseases through innovative vaccine technology

LinkedIn-button

Our Mission

To partner with governmental
agencies, NGO's and private entities
to help to reduce the burden of diseases

LinkedIn-button

Intravacc to the point

  • Founded in 2013
  • HQ at Utrecht Science Park Bilthoven
  • Experts in vaccinology
  • Clinical development & manufacturing organization
  • 2000+ m2 state-of the art facilities, incl BSL-2/3 & GMP
  • ISO 9001 and ISO 14001 certified
  • >140 high qualified employees
  • 50+ customers worldwide
  • 300+ scientific publications in peer reviewed journals
LinkedIn-button

About us

Certifications

Intravacc performs her activities in compliance with applicable laws and regulations. To support the customers expectations in the most efficient way, the quality management system is in compliance with ISO9001.

The care for employees and for the environment is a top priority for Intravacc. Sustainability is important to guarantee a safe and health environment for the future. Therefore, Intravacc implemented an environmental management system according to ISO14001.
An external company regularly audits the management systems for ISO9001 and ISO14001 to assure continuously compliance.

For the manufacturing and quality control of clinical trial materials, Intravacc B.V. has a manufacturing license granted by the Dutch Authorities. Regular inspections are performed by the Dutch Inspectorate of Health to verify compliance.

ISO 9001 certificate
ISO 14001 certificate
GMP manufacturer’s license
LinkedIn-button

About us

Latest News

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the German Center for Neurogenerative Diseases (DZNE), have been awarded a funding of  € 2.5 million…

  • Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
  • ALS vaccine is targeting the most common genetic ALS variant
  • 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene
Read more

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors Bilthoven, the Netherlands, 5 July 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced the publication of the 2021 annual report and the expansion of its management team, with…

  • Publication annual report 2021
  • Appointment of a Chief Business Officer
  • Appointment of a Director vaccine process development
  • Chief Financial Officer joins the Board of Directors
Read more

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced the signing of an exclusive licensing agreement with Beijing Zhifei…

  • Avacc 3 has significant advantages over existing whooping cough vaccines
  • Second major OMV platform licensing agreement with pharmaceutical company
  • Over 24 million cases of whooping cough per year world-wide
Read more
LinkedIn-button

About us

Media

LinkedIn-button

About us

Join our Community

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.